ReviewJournal of internal medicine2012
Allergen-specific immunotherapy: from therapeutic vaccines to prophylactic approaches.
Review in Journal of internal medicine, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 54 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
54 citing papers in PubMed.
- Maternal allergen-specific IgG might protect the child against allergic sensitization.The Journal of allergy and clinical immunology · 2019Trial
- Vaccination of nonallergic individuals with recombinant hypoallergenic fragments of birch pollen allergen Bet v 1: Safety, effects, and mechanisms.The Journal of allergy and clinical immunology · 2019Trial
- Safety and efficacy of immunotherapy with the recombinant B-cell epitope-based grass pollen vaccine BM32.The Journal of allergy and clinical immunology · 2018Trial
- Mechanisms, safety and efficacy of a B cell epitope-based vaccine for immunotherapy of grass pollen allergy.EBioMedicine · 2016Trial
- Skin test evaluation of a novel peptide carrier-based vaccine, BM32, in grass pollen-allergic patients.The Journal of allergy and clinical immunology · 2015Trial
- Deciphering Allergen Peptides for Dermatological and Cosmetic Applications with Explainable Artificial Intelligence.Journal of proteome research · 2026Article
- Evaluation of the Biological Standardization of Native Der p 1, Der p 2 and Der p 23 Proteins Isolated from Natural Allergen Source.International journal of molecular sciences · 2026Article
- Transient Expression and Immunogenicity Assessment of theVaccines · 2026Article
- Art an 3 as a candidate recombinant antigen for Artemisia pollen immunotherapy: comparative efficacy and mechanistic insights.Frontiers in medicine · 2026Article
- Advances in Shellfish Allergy Therapy: From Current Approaches to Future Strategies.Clinical reviews in allergy & immunology · 2025Review
- Allergen immunotherapy for the control of moderate to severe allergic asthma: an evidence-based conjoint analysis to define candidate patient profiles in Spain and Portugal.Frontiers in allergy · 2025Article
- Effect of Allergen-Specific Immunotherapy on Transcriptomic Changes in Canine Atopic Dermatitis.International journal of molecular sciences · 2023Article
- Adoptive transfer of allergen-expressing B cells prevents IgE-mediated allergy.Frontiers in immunology · 2023Article
- Recombinant multimeric dog allergen prevents airway hyperresponsiveness in a model of asthma marked by vigorous TAllergy · 2022Article
- Article
- pH-dependent structural diversity of profilin allergens determines thermal stability.Frontiers in allergy · 2022Article
- Article
- Resistance of parvalbumin to gastrointestinal digestion is required for profound and long-lasting prophylactic oral tolerance.Allergy · 2020Article
- Two years of treatment with the recombinant grass pollen allergy vaccine BM32 induces a continuously increasing allergen-specific IgGEBioMedicine · 2019Article
- Recombinant allergens for immunotherapy: state of the art.Current opinion in allergy and clinical immunology · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Immunoglobulin E-mediated allergies affect more than 25% of the population. Allergen exposure induces a variety of symptoms in allergic patients, which include rhinitis, conjunctivitis, asthma, dermatitis, food allergy and life-threatening systemic anaphylaxis. At present, allergen-specific immunotherapy (SIT), which is based on the administration of the disease-causing allergens, is the only disease-modifying treatment for allergy. Current therapeutic allergy vaccines are still prepared from relatively poorly defined allergen extracts. However, with the availability of the structures of the most common allergen molecules, it has become possible to produce well-defined recombinant and synthetic allergy vaccines that allow specific targeting of the mechanisms of allergic disease. Here we provide a summary of the development and mechanisms of SIT, and then review new forms of therapeutic vaccines that are based on recombinant and synthetic molecules. Finally, we discuss possible allergen-specific strategies for prevention of allergic disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.